Takeda has secured approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its 1mg/5mg FRUZAQLA capsules (fruquintinib) to treat unresectable advanced or recurrent colorectal cancer (CRC). The approval positions the treatment as a new option for CRC that has progressed following chemotherapy. The gold standard of business intelligence.
The latest approval is based on the outcomes of the international Phase III FRESCO-2 trial. Conducted across multiple regions including the US, Europe, Japan and Australia, the study assessed FRUZAQLA plus best supportive care (BSC) compared to placebo plus BSC. The trial also met all primary and key secondary endpoints.
FRUZAQLA was demonstrated to significantly improve both overall survival and progression-free survival in trial subjects. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form The asset’s safety profile was in line with those observed in previous fruquintinib monotherapy studies.
It is an oral inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2, and -3, and offers enhanced selectivity that limits off-target kinase activity, allowing for sustained target.